VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
ASSA ABLOY AB vs Novartis AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
ASSA ABLOY AB
ASSA-B · Nasdaq Stockholm
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into ASSA ABLOY AB's moat claims, evidence, and risks.
View ASSA-B analysisNovartis AG
NOVN · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novartis AG's moat claims, evidence, and risks.
View NOVN analysisComparison highlights
- Moat score gap: ASSA ABLOY AB leads (76 / 100 vs 65 / 100 for Novartis AG).
- Segment focus: ASSA ABLOY AB has 5 segments (32.9% in Entrance Systems); Novartis AG has 5 segments (29.3% in Oncology).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: ASSA ABLOY AB has 4 moat types across 2 domains; Novartis AG has 4 across 3.
Primary market context
ASSA ABLOY AB
Entrance Systems
Entrance automation and industrial door solutions (pedestrian automatic doors, industrial doors, loading dock equipment, service/maintenance)
Global
Commercial/industrial facilities via distributors, installers and service channels
OEM + service/maintenance provider
32.9%
Novartis AG
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
Global
Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels
Originator developer, manufacturer, and marketer of oncology therapies
29.3%
Side-by-side metrics
Moat coverage
Shared moat types
ASSA ABLOY AB strengths
Novartis AG strengths
Segment mix
ASSA ABLOY AB segments
Full profile >Opening Solutions EMEIA
Oligopoly
Opening Solutions Americas
Oligopoly
Opening Solutions Asia Pacific
Competitive
Global Technologies
Oligopoly
Entrance Systems
Oligopoly
Novartis AG segments
Full profile >Cardiovascular, Renal and Metabolic
Oligopoly
Immunology
Oligopoly
Neuroscience
Oligopoly
Oncology
Oligopoly
Established Brands
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.